RECOMBINANT ADAMTS13 (rADAMTS13), -, RITUXIMAB
TAK-755-2001
Phase 2 small_molecule active
Quick answer
RECOMBINANT ADAMTS13 (rADAMTS13), -, RITUXIMAB for Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Immune-mediated thrombotic thrombocytopenic purpura (iTTP)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active